OR WAIT null SECS
November 12, 2024
Ascend is partnering with EW Healthcare Partners to expand capabilities in the United States.
November 11, 2024
The new Institute for Cell Therapy Discovery and Innovation will utilize expertise to develop cell therapies for cancer, autoimmune diseases, and infections.
November 08, 2024
Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months.
A £520 million investment for manufacturing capacity was announced by Chancellor of the Exchequer, Rachel Reeves, but academic and industry leaders stress the money should be used to train personnel.
The companies will work to create climate-friendly pMDIs using Orbia’s low global warming potential propellant.
In the collaboration, the new company, Oblenio Bio, has been granted an exclusive option to license LBL-051, a tri-specific T-cell engager antibody, from Leads Biolabs.
November 07, 2024
A genetic medicines customer has selected the company’s binders for commercial development of the customer’s product.
The merger agreement is valued at approximately $1.1 billion.
Synaffix, a Lonza company, has licensed its ADC technology to BigHat Biosciences to be combined with the latter's ML design platform to develop new ADCs
November 06, 2024
Data governance, data integrity, and data quality are all widely used terms, but what do they actually mean and how are they connected?